de novo acute lymphoblastic leukemia
Conditions
Interventions
After enrollment, we will evaluate CAP value using transient elastography to assess steatosis before initiating the treatment for acute lymphoblastic leukemia. CAP value is measured with evaluating ci
Sponsors
Tanoshima Reo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. De novo pediatric patients (age < 20 years old) who were diagnosed as acute lymphoblastic leukemia, planning to perform chemotherapy in our hospital. 2. Performance status 0-2 3. Patients whose legal gurdians provide written informed consents.
Exclusion criteria
Exclusion criteria: 1. Patients who have chronic hepatitis such as HBV or HCV. 2. Patients who are extremely anxious for the exam. 3. Patients who are allergic to ultrasound gel. 4. Patients whose body mass index are more than 30. 5. Patients who have preivious hisotory of malignant diseases or cancer chemotherapy. 6. Other reasons for inapproate candidates of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients whose Controlled Attenuation Parameter (CAP) were above 225 dB/m. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare of CAP between pretreatment and post-induction therapy. To investigate chronological changes of CAP. To evaluate factors of CAP > 225 dB/, after induction therapy (AST, ALT, total cholesterol, triglyceride) | — |
Contacts
Public ContactReo Tanoshima
Yokohama City University Hospital
Outcome results
None listed